Ractigen is an early-stage pharmaceutical company.
Ractigen is an early-stage pharmaceutical company committed to bringing to market first-in-class therapies designed to selectively restore the expression of therapeutic genes silenced in diseased cells. Its core technology is based on a paradigm-shifting discovery made at the University of California San Francisco (UCSF) known as RNA activation (RNAa). Founded in 2016 by the pioneers in the field, Ractigen is developing a rich pipeline of candidate medicines for patients with unmet need.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 27, 2022 | Series A | $30M | 5 | SDIC Venture Capital | — | Detail |
Feb 18, 2021 | Series A | ¥110M | 3 | GL Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
SDIC Venture Capital | Yes | Series A |
GL Ventures | Yes | Series A |
China Singapore Suzhou Industrial Park Ventures | — | Series A |
Eisai | — | Series A |
Newzone Ventures | — | Series A |
Xianghe Capital | — | Series A |
Boyi Fund | — | Series A |
Longmen Capital | — | Series A |